RCT | Evaluating subcutaneous rituximab for the first-line treatment of low–tumor burden follicular lymphoma
3 May, 2023 | 15:07h | UTCRandomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low–Tumor Burden Follicular Lymphoma: Results of a LYSA Study – Journal of Clinical Oncology (link to abstract – $ for full-text)